drugset / Trial / NCT04329325
Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test whether blinatumomab in combination with TKI therapy (such as dasatinib) is an effective treatment for people with Ph+ ALL. Researchers want to improve the response to standard-of-care treatment of corticosteroids + TKI therapy by adding the study drug, blinatumomab.
Timeline
- Start
- 2020-03-30
- Primary completion
- 2027-03
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Blinatumomab | Monoclonal antibody | 15 ug/m2 | Intravenous |
| Subject | Blinatumomab | Monoclonal antibody | 28 ug | Intravenous |
| Background | Dexamethasone | Small molecule | 10 mg/m2 | — |
| Background | Methotrexate | Small molecule | 12 mg | Intrathecal |
| Background | dasatinib anhydrous | Small molecule | 140 mg | Oral |